{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T16:21:00Z","timestamp":1770567660140,"version":"3.49.0"},"reference-count":35,"publisher":"Becaris Publishing Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            In the US, lanreotide and injectable octreotide are commonly used to treat acromegaly. For most patients, the recommended injection administration regimen is every 4\u00a0weeks, or 13-times over the course of 1\u00a0year. The study aimed to quantify the proportion of patients who used a number of injections that is beyond the standard recommended regimen and to assess whether high frequency (HF) use is associated with higher healthcare resource utilization and costs.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            IQVIA Pharmetrics Plus data between 1 January 2013 and 30 June 2023 was used to conduct a retrospective, observational study of acromegaly patients who used injectable octreotide or lanreotide for at least 2\u00a0years. The primary study outcomes were the number of injections and HF use. HF use is defined as having observed more than 13 injections over a 1-year observation period.\n            <jats:bold>Results:<\/jats:bold>\n            There were 420 patients with acromegaly who used injectable octreotide (n\u00a0=\u00a0250) or lanreotide (n\u00a0=\u00a0170) for a median of 4\u00a0years. HF use was observed in 32.4% of injectable octreotide users and 30.6% of lanreotide users. Over the course of 1\u00a0year, mean total healthcare costs were significantly higher among HF users compared with non-HF users among patients treated with injectable octreotide ($130,238 vs $85,964, p\u00a0&lt;\u00a00.001) or lanreotide ($143,975 vs $96,518, p\u00a0&lt;\u00a00.001). Additionally, 10% of HF users incurred $238,070\u2013$281,167 or more. Based on the average cost per injection, patients with HF use had an additional $12,803\u2013$13,480 in injection costs each year.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Among those who are consistently treated, nearly a third of patients with acromegaly are HF users of lanreotide or injectable octreotide. The economic burden of HF use is high. Given the high proportion of patients who require administration beyond what is indicated on approved drug labels, further evaluation of new therapies is warranted.\n          <\/jats:p>","DOI":"10.57264\/cer-2025-0070","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T11:59:47Z","timestamp":1752753587000},"source":"Crossref","is-referenced-by-count":1,"title":["Dosing patterns, healthcare resource utilization and costs among acromegaly patients who consistently use lanreotide and injectable octreotide"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4861-4285","authenticated-orcid":false,"given":"Tiffany P","family":"Quock","sequence":"first","affiliation":[{"name":"Crinetics Pharmaceuticals, San Diego, CA 92121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-6153","authenticated-orcid":false,"given":"Eunice","family":"Chang","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7110-9463","authenticated-orcid":false,"given":"Ashis K","family":"Das","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8789-1384","authenticated-orcid":false,"given":"Amanda","family":"Speller","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0818-5113","authenticated-orcid":false,"given":"Marian H","family":"Tarbox","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3567-0862","authenticated-orcid":false,"given":"Stacy K","family":"Rattana","sequence":"additional","affiliation":[{"name":"Crinetics Pharmaceuticals, San Diego, CA 92121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3591-7293","authenticated-orcid":false,"given":"Ingrid E","family":"Paulson","sequence":"additional","affiliation":[{"name":"Crinetics Pharmaceuticals, San Diego, CA 92121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-5536","authenticated-orcid":false,"given":"Michael S","family":"Broder","sequence":"additional","affiliation":[{"name":"ADVI Health, LLC, Washington, DC 20004, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"11","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu M","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 10(11), 804\u2013826 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mayocp.2021.11.007","article-title":"Diagnosis and treatment of acromegaly: an update","volume":"97","author":"Ershadinia N","year":"2022","unstructured":"Ershadinia N, Tritos NA. Diagnosis and treatment of acromegaly: an update. Mayo Clin. Proc. 97(2), 333\u2013346 (2022).","journal-title":"Mayo Clin. Proc."},{"issue":"4","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11102-013-0506-0","article-title":"Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases","volume":"17","author":"Broder MS","year":"2014","unstructured":"Broder MS, Neary MP, Chang E, Cherepanov D, Katznelson L. Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary 17(4), 333\u2013341 (2014).","journal-title":"Pituitary"},{"issue":"3","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11102-012-0432-6","article-title":"Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases","volume":"16","author":"Burton T","year":"2013","unstructured":"Burton T, Le Nestour E, Bancroft T, Neary M. Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary 16(3), 354\u2013362 (2013).","journal-title":"Pituitary"},{"issue":"10","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"bvad104","DOI":"10.1210\/jendso\/bvad104","article-title":"Treatment patterns, adherence, persistence, and health care resource utilization in acromegaly: a real-world analysis","volume":"7","author":"Fleseriu M","year":"2023","unstructured":"Fleseriu M, Barkan A, Brue T Treatment patterns, adherence, persistence, and health care resource utilization in acromegaly: a real-world analysis. J. Endocr. Soc. 7(10), bvad104 (2023).","journal-title":"J. Endocr. Soc."},{"issue":"4","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina A","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A Multidisciplinary management of acromegaly: a consensus. Rev. Endocr. Metab. Disord. 21(4), 667\u2013678 (2020).","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"1","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","article-title":"Consensus on criteria for acromegaly diagnosis and remission","volume":"27","author":"Giustina A","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1), 7\u201322 (2024).","journal-title":"Pituitary"},{"issue":"9","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed S","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P A consensus statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14(9), 552\u2013561 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"issue":"7","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2017-00142","article-title":"High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study","volume":"102","author":"Giustina A","year":"2017","unstructured":"Giustina A, Mazziotti G, Cannav\u00f2 S High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J. Clin. Endocrinol. Metab. 102(7), 2454\u20132464 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-09-0372","article-title":"High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial","volume":"161","author":"Giustina A","year":"2009","unstructured":"Giustina A, Bonadonna S, Bugari G High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur. J. Endocrinol. 161(2), 331\u2013338 (2009).","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"e_1_3_8_13_2","first-page":"37","article-title":"Clinical pharmacology of oral octreotide capsules for the treatment of acromegaly","volume":"20","author":"Uygur MM","year":"2024","unstructured":"Uygur MM, Villanova M, Frara S, Giustina A. Clinical pharmacology of oral octreotide capsules for the treatment of acromegaly. Touch Rev. Endocrinol. 20(1), 37\u201342 (2024).","journal-title":"Touch Rev. Endocrinol."},{"issue":"5","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson ME","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40(5), 373\u2013383 (1987).","journal-title":"J. Chronic Dis."},{"issue":"4","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11102-016-0725-2","article-title":"Challenges in the diagnosis and management of acromegaly: a focus on comorbidities","volume":"19","author":"Abreu A","year":"2016","unstructured":"Abreu A, Tovar AP, Castellanos R Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary 19(4), 448\u2013457 (2016).","journal-title":"Pituitary"},{"key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"101389","DOI":"10.1016\/j.ghir.2021.101389","article-title":"Economic and clinical burden of comorbidities among patients with acromegaly","volume":"59","author":"Whittington MD","year":"2021","unstructured":"Whittington MD, Munoz KA, Whalen JD, Ribeiro-Oliveira A, Campbell JD. Economic and clinical burden of comorbidities among patients with acromegaly. Growth Horm. IGF Res. 59, 101389 (2021).","journal-title":"Growth Horm. IGF Res."},{"key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"101431","DOI":"10.1016\/j.ghir.2021.101431","article-title":"Risk factors associated with thyroid nodular disease in acromegalic patients: a case-cohort study in a tertiary center","volume":"60","author":"Vargas-Ortega G","year":"2021","unstructured":"Vargas-Ortega G, Romero-Gameros CA, Rend\u00f3n-Macias ME Risk factors associated with thyroid nodular disease in acromegalic patients: a case-cohort study in a tertiary center. Growth Horm. IGF Res. 60\u201361, 101431 (2021).","journal-title":"Growth Horm. IGF Res."},{"issue":"12","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"E392","DOI":"10.1210\/jc.2010-1253","article-title":"Increased psychopathology and maladaptive personality traits, but normal cognitive functioning, in patients after long-term cure of acromegaly","volume":"95","author":"Tiemensma J","year":"2010","unstructured":"Tiemensma J, Biermasz NR, van der Mast RC Increased psychopathology and maladaptive personality traits, but normal cognitive functioning, in patients after long-term cure of acromegaly. J. Clin. Endocrinol. Metab. 95(12), E392\u2013E402 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"e_1_3_8_19_2","unstructured":"FDA. \u201cSandostatin LAR Depot drug label\u201d (2024). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/021008Orig1s047lbl.pdf"},{"key":"e_1_3_8_20_2","unstructured":"FDA. \u201cSomatuline Depot (lanreotide) drug label\u201d (2014). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022074s011lbl.pdf"},{"key":"e_1_3_8_21_2","unstructured":"Novartis Pharmaceuticals Corporation. Sandostatin LAR\u00ae Depot (octreotide acetate for injectable suspension) [prescribing information] (2019). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021008s043lbl.pdf"},{"issue":"1","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/13696998.2021.1898968","article-title":"Burden of acromegaly in the United States: increased health services utilization, location of care, and costs of care","volume":"24","author":"Ribeiro-Oliveira A","year":"2021","unstructured":"Ribeiro-Oliveira A, Brook RA, Munoz KA Burden of acromegaly in the United States: increased health services utilization, location of care, and costs of care. J. Med. Econ 24(1), 432\u2013439 (2021).","journal-title":"J. Med. Econ"},{"issue":"12","key":"e_1_3_8_23_2","first-page":"1106","article-title":"Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis","volume":"21","author":"Placzek H","year":"2015","unstructured":"Placzek H, Xu Y, Mu Y, Begelman SM, Fisher M. Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis. J. Manag. Care Spec. Pharm. 21(12), 1106\u20131112 (2015).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","article-title":"Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands","volume":"12","author":"Fleseriu M","year":"2021","unstructured":"Fleseriu M, Molitch M, Dreval A Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands. Front. Endocrinol. 12, 627711 (2021).","journal-title":"Front. Endocrinol."},{"issue":"1","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer EB","year":"2020","unstructured":"Geer EB, Sisco J, Adelman DT Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr. Disord. 20(1), 117 (2020).","journal-title":"BMC Endocr. Disord."},{"issue":"3","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger CJ","year":"2016","unstructured":"Strasburger CJ, Karavitaki N, St\u00f6rmann S Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur. J. Endocrinol. 174(3), 355\u2013362 (2016).","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"e00158","DOI":"10.1002\/edm2.158","article-title":"Management of persistent acromegaly following primary therapy: the current landscape in the UK","volume":"3","author":"Kyriakakis N","year":"2020","unstructured":"Kyriakakis N, Seejore K, Hanafy A, Murray RD. Management of persistent acromegaly following primary therapy: the current landscape in the UK. Endocrinol. Diabetes Metab. 3(3), e00158 (2020).","journal-title":"Endocrinol. Diabetes Metab."},{"issue":"9","key":"e_1_3_8_28_2","article-title":"A comprehensive review of four clinical practice guidelines of acromegaly","volume":"14","author":"Ogedegbe OJ","year":"2022","unstructured":"Ogedegbe OJ, Cheema AY, Khan MA A comprehensive review of four clinical practice guidelines of acromegaly. Cureus 14(9), e28722 (2022).","journal-title":"Cureus"},{"issue":"2","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000317314","article-title":"Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling IGF-I levels in acromegaly","volume":"92","author":"Mattar P","year":"2010","unstructured":"Mattar P, Alves Martins MR, Abucham J. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling IGF-I levels in acromegaly. Neuroendocrinology 92(2), 120\u2013127 (2010).","journal-title":"Neuroendocrinology"},{"issue":"3","key":"e_1_3_8_30_2","first-page":"278","article-title":"Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature","volume":"66","author":"Kizilgul M","year":"2022","unstructured":"Kizilgul M, Duger H, Nasiroglu NI Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature. Arch. Endocrinol. Metab. 66(3), 278\u2013285 (2022).","journal-title":"Arch. Endocrinol. Metab."},{"issue":"2","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11102-010-0272-1","article-title":"Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR","volume":"14","author":"Vilar L","year":"2010","unstructured":"Vilar L, Azevedo MF, Naves LA Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary 14(2), 148\u2013156 (2010).","journal-title":"Pituitary"},{"issue":"4","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1507\/endocrj.EJ12-0272","article-title":"Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature","volume":"60","author":"Suda K","year":"2013","unstructured":"Suda K, Inoshita N, Iguchi G Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Endocr. J. 60(4), 507\u2013515 (2013).","journal-title":"Endocr. J."},{"issue":"3","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40801-015-0039-0","article-title":"Treatment patterns and economic burden in patients treated for acromegaly in the USA","volume":"2","author":"Chuang C-C","year":"2015","unstructured":"Chuang C-C, Bhurke S, Chen S-Y, Dinet J, Brulais S, Gabriel S. Treatment patterns and economic burden in patients treated for acromegaly in the USA. Drugs - Real World Outcomes 2(3), 299\u2013309 (2015).","journal-title":"Drugs - Real World Outcomes"},{"issue":"2","key":"e_1_3_8_34_2","first-page":"41","article-title":"Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the growth hormone research society and the pituitary society","volume":"26","author":"Lim EM","year":"2005","unstructured":"Lim EM, Pullan P. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the growth hormone research society and the pituitary society. Clin. Biochem. Rev. 26(2), 41\u201343 (2005).","journal-title":"Clin. Biochem. Rev."},{"key":"e_1_3_8_35_2","unstructured":"U.S. Bureau of Labor Statistics. \u201cCPI inflation calculator - consumer price index for all urban consumers (CPI-U)\u201d (2024). Available from: https:\/\/www.bls.gov\/data\/inflation_calculator.htm"},{"issue":"12","key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/jama.1988.03410120089033","article-title":"The quality of care: how can it be assessed?","volume":"260","author":"Donabedian A","year":"1988","unstructured":"Donabedian A. The quality of care: how can it be assessed? JAMA 260(12), 1743\u20131748 (1988).","journal-title":"JAMA"},{"key":"e_1_3_8_37_2","volume-title":"Crossing the quality chasm: a new health system for the 21st century","author":"Institute of Medicine (US) Committee on Quality of Health Care in America","year":"2001","unstructured":"Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st century. National Academies Press (US), DC, USA (2001)."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:54:11Z","timestamp":1756457651000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.57264\/cer-2025-0070"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0070","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"e250070"}}